ProteoTech and Tasly Pharmaceuticals Announce Alzheimer's Disease Drug Development Agreement for Exebryl-1(R)

Potential disease-modifying Alzheimer's treatment targeting beta-amyloid and tau protein advancing through collaboration between ProteoTech Inc. and major Chinese company, Tasly Pharmaceuticals.

KIRKLAND, Washington, October 4, 2010 - Tasly Pharmaceutical Co., Ltd. (Tianjin, China) and ProteoTech, Inc.
(Kirkland, WA, USA) today announced an agreement to co-develop ProteoTech's
novel small molecule therapeutic, Exebryl-1(R), for the treatment of
mild-to-moderate Alzheimer's disease. Exebryl-1(R) has been shown to inhibit
beta-amyloid protein aggregate formation in brain, as well as disaggregate
amyloid plaques that are already present. The drug has also shown specificity
against tau protein aggregates and may be the first therapeutic targeting
beta-amyloid and tau protein associated with this disease.

    (Logo: photos.prnewswire.com/prnh/20090226/SF76109LOGO)
    (Logo: www.newscom.com/cgi-bin/prnh/20090226/SF76109LOGO)

The collaboration will focus on moving the clinical development of this
drug though the regulatory process in China and the US. Terms of the deal
were not disclosed but will include an upfront payment, development costs and
research funding to ProteoTech according to Manuel Menendez, Managing Partner
of Nobel Pacific, who acted as an advisor to both companies. Tasly will gain
rights for Exebryl-1(R) for China and ProteoTech will retain rights for the
United States and the rest of the world.

"We are very happy with this opportunity to work with the team at
ProteoTech and we feel that Exebryl-1(R) will become a very important
medication in China against the growing epidemic of Alzheimer's disease"
stated Dr. Henry Sun, Vice President of Tasly Group and President of Tasly
Pharmaceuticals, Inc.

ProteoTech CEO, Steve Runnels said "The opportunity for this
collaboration with a major international pharmaceutical company is very
exciting for us. We are very fortunate to have Tasly as a partner and their
experience in drug development, especially in China, provides an opportunity
to accelerate Exebryl-1(R) through clinical development. We look forward to a
successful Exebryl-1(R) collaboration with Tasly and the potential
development of other promising technologies in our pipeline as well."

About ProteoTech: ProteoTech is a private drug development company in
Kirkland, WA and is focused on targeting amyloid diseases. Besides
Exebryl-1(R) for Alzheimer's disease treatment, the Company is also in late
stage pre-clinical development of Synuclere(TM)
(www.proteotech.com/pipeline/synuclere.html) for the treatment of
Parkinson's disease, Systebryl(TM)
(www.proteotech.com/pipeline/systebryl.html) for the treatment of
Systemic Amyloidosis, and is in late stage pre-clinical development for a
novel small peptide called PeptiClere(TM)
(www.proteotech.com/pipeline/pepticlere.html) for the treatment of
Alzheimer's disease. For more information please see the Company web site at
www.proteotech.com.

About Tasly: Tasly was founded in May 1994 in Tianjin, China. With the
pharmaceutical industry as its center, Tasly has become a leading group of
high technology companies, whose scope of business includes modern TCM,
ethical pharmaceutical and biological medications, healthcare products and
functional foods covering the fields of research and development,
manufacturing and distribution. Trading on the Shanghai Stock Exchange
(#600535), Tasly has consistently kept true to the core values of adding to
shareholder value as well as social responsibility and philanthropy. For more
information please see the company web site at www.tasly.com.

Steve Runnels, +1-425-823-0400, Ext. 16, runnels at proteotech.com